162 related articles for article (PubMed ID: 19216793)
1. Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses.
Gulati S; Smith DF; Air GM
Virol J; 2009 Feb; 6():22. PubMed ID: 19216793
[TBL] [Abstract][Full Text] [Related]
2. Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
Bauer K; Dürrwald R; Schlegel M; Pfarr K; Topf D; Wiesener N; Dahse HM; Wutzler P; Schmidtke M
Med Microbiol Immunol; 2012 Feb; 201(1):61-72. PubMed ID: 21688167
[TBL] [Abstract][Full Text] [Related]
3. Evolution of oseltamivir resistance mutations in Influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice.
Pizzorno A; Abed Y; Plante PL; Carbonneau J; Baz M; Hamelin MÈ; Corbeil J; Boivin G
Antimicrob Agents Chemother; 2014 Nov; 58(11):6398-405. PubMed ID: 25114143
[TBL] [Abstract][Full Text] [Related]
4. The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding.
Mohr PG; Deng YM; McKimm-Breschkin JL
Virol J; 2015 Apr; 12():67. PubMed ID: 25896455
[TBL] [Abstract][Full Text] [Related]
5. Difluorosialic acids, potent novel influenza virus neuraminidase inhibitors, induce fewer drug resistance-associated neuraminidase mutations than does oseltamivir.
Tai SH; Agafitei O; Gao Z; Liggins R; Petric M; Withers SG; Niikura M
Virus Res; 2015 Dec; 210():126-32. PubMed ID: 26247418
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.
Richard M; Ferraris O; Erny A; Barthélémy M; Traversier A; Sabatier M; Hay A; Lin YP; Russell RJ; Lina B
Antimicrob Agents Chemother; 2011 Jun; 55(6):2942-52. PubMed ID: 21422222
[TBL] [Abstract][Full Text] [Related]
7. Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2.
Trebbien R; Christiansen CB; Fischer TK
J Clin Virol; 2018 May; 102():1-6. PubMed ID: 29448067
[TBL] [Abstract][Full Text] [Related]
8. Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS).
Roosenhoff R; Schutten M; Reed V; Clinch B; van der Linden A; Fouchier RAM; Fraaij PLA
Antiviral Res; 2021 May; 189():105060. PubMed ID: 33713731
[TBL] [Abstract][Full Text] [Related]
9. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
Sheu TG; Deyde VM; Okomo-Adhiambo M; Garten RJ; Xu X; Bright RA; Butler EN; Wallis TR; Klimov AI; Gubareva LV
Antimicrob Agents Chemother; 2008 Sep; 52(9):3284-92. PubMed ID: 18625765
[TBL] [Abstract][Full Text] [Related]
10. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.
Abed Y; Nehmé B; Baz M; Boivin G
Antiviral Res; 2008 Feb; 77(2):163-6. PubMed ID: 17919743
[TBL] [Abstract][Full Text] [Related]
11. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
[TBL] [Abstract][Full Text] [Related]
12. Mismatched hemagglutinin and neuraminidase specificities in recent human H3N2 influenza viruses.
Gulati U; Wu W; Gulati S; Kumari K; Waner JL; Air GM
Virology; 2005 Aug; 339(1):12-20. PubMed ID: 15950996
[TBL] [Abstract][Full Text] [Related]
13. Drug susceptibility of influenza A/H3N2 strains co-circulating during 2009 influenza pandemic: first report from Mumbai.
Gohil DJ; Kothari ST; Shinde PS; Chintakrindi AS; Meharunkar R; Warke RV; Kanyalkar MA; Chowdhary AS; Deshmukh RA
Infect Genet Evol; 2015 Jan; 29():75-81. PubMed ID: 25461259
[TBL] [Abstract][Full Text] [Related]
14. In vitro characterization of naturally occurring influenza H3NA- viruses lacking the NA gene segment: toward a new mechanism of viral resistance?
Moules V; Ferraris O; Terrier O; Giudice E; Yver M; Rolland JP; Bouscambert-Duchamp M; Bergeron C; Ottmann M; Fournier E; Traversier A; Boule C; Rivoire A; Lin Y; Hay A; Valette M; Marquet R; Rosa-Calatrava M; Naffakh N; Schoehn G; Thomas D; Lina B
Virology; 2010 Sep; 404(2):215-24. PubMed ID: 20627352
[TBL] [Abstract][Full Text] [Related]
15. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds.
Abed Y; Baz M; Boivin G
Antivir Ther; 2006; 11(8):971-6. PubMed ID: 17302366
[TBL] [Abstract][Full Text] [Related]
16. Neuraminidase inhibitor susceptibility and neuraminidase enzyme kinetics of human influenza A and B viruses circulating in Thailand in 2010-2015.
Tewawong N; Marathe BM; Poovorawan Y; Vongpunsawad S; Webby RJ; Govorkova EA
PLoS One; 2018; 13(1):e0190877. PubMed ID: 29324781
[TBL] [Abstract][Full Text] [Related]
17. Evolution of the susceptibility to antiviral drugs of A/H3N2 influenza viruses isolated in France from 2002 to 2005.
Ferraris O; Kessler N; Valette M; Lina B
Vaccine; 2006 Nov; 24(44-46):6656-9. PubMed ID: 16797804
[TBL] [Abstract][Full Text] [Related]
18. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.
Abed Y; Baz M; Boivin G
J Infect Dis; 2009 Jan; 199(2):180-3. PubMed ID: 19046066
[TBL] [Abstract][Full Text] [Related]
19. The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
Mishin VP; Sleeman K; Levine M; Carney PJ; Stevens J; Gubareva LV
Antiviral Res; 2014 Jan; 101():93-6. PubMed ID: 24239666
[TBL] [Abstract][Full Text] [Related]
20. Structural and evolutionary characteristics of HA, NA, NS and M genes of clinical influenza A/H3N2 viruses passaged in human and canine cells.
Zhirnov OP; Vorobjeva IV; Saphonova OA; Poyarkov SV; Ovcharenko AV; Anhlan D; Malyshev NA
J Clin Virol; 2009 Aug; 45(4):322-33. PubMed ID: 19546028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
